4月15日,映恩生物-B(HK09606,股价205港元,市值175.1亿港元)在港交所挂牌上市,这是港交所2022年以来融资规模最大的“18A”生物科技上市公司(指适用港交所上市规则第18A章的公司)。 映恩生物每股定价94.6港元,共发行1733.23万股。上市首日开盘后,映恩生物一路走高,盘中最高涨幅曾超过130%。截至收盘,映恩生物日涨幅为116.7%,不计手续费,每手赚11040港元。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.